ProQR Therapeutics N.V (NASDAQ: PRQR)’s stock price has increased by 1.76 compared to its previous closing price of 3.98. However, the company has seen a 11.26% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-25 that LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR.
Is It Worth Investing in ProQR Therapeutics N.V (NASDAQ: PRQR) Right Now?
PRQR has 36-month beta value of 0.24. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PRQR is 66.65M, and currently, short sellers hold a 1.02% ratio of that float. The average trading volume of PRQR on November 13, 2024 was 1.31M shares.
PRQR’s Market Performance
PRQR stock saw an increase of 11.26% in the past week, with a monthly gain of 123.76% and a quarterly increase of 81.61%. The volatility ratio for the week is 7.38%, and the volatility levels for the last 30 days are 15.13% for ProQR Therapeutics N.V (PRQR). The simple moving average for the last 20 days is 8.17% for PRQR stock, with a simple moving average of 88.45% for the last 200 days.
Analysts’ Opinion of PRQR
Many brokerage firms have already submitted their reports for PRQR stocks, with Raymond James repeating the rating for PRQR by listing it as a “Strong Buy.” The predicted price for PRQR in the upcoming period, according to Raymond James is $14 based on the research report published on October 29, 2024 of the current year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see PRQR reach a price target of $2. The rating they have provided for PRQR stocks is “Buy” according to the report published on November 08th, 2023.
JMP Securities gave a rating of “Mkt Outperform” to PRQR, setting the target price at $5 in the report published on March 30th of the previous year.
PRQR Trading at 53.55% from the 50-Day Moving Average
After a stumble in the market that brought PRQR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.34% of loss for the given period.
Volatility was left at 15.13%, however, over the last 30 days, the volatility rate increased by 7.38%, as shares surge +1.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +114.84% upper at present.
During the last 5 trading sessions, PRQR rose by +11.85%, which changed the moving average for the period of 200-days by +88.48% in comparison to the 20-day moving average, which settled at $3.75. In addition, ProQR Therapeutics N.V saw 104.55% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PRQR
Current profitability levels for the company are sitting at:
- -1.85 for the present operating margin
- 0.91 for the gross margin
The net margin for ProQR Therapeutics N.V stands at -1.4. The total capital return value is set at -0.35. Equity return is now at value -67.62, with -19.30 for asset returns.
Based on ProQR Therapeutics N.V (PRQR), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -1.95.
Currently, EBITDA for the company is -31.69 million with net debt to EBITDA at 2.26. When we switch over and look at the enterprise to sales, we see a ratio of 22.0. The receivables turnover for the company is 3.38for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.
Conclusion
To put it simply, ProQR Therapeutics N.V (PRQR) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
